Bank of America downgraded Hologic HOLX from Buy to Neutral and raised the price target from $23.00 to $24.00.
Bank of America noted, "We are downgrading Hologic to Neutral driven largely by valuation following a 22% increase since early December (vs the medical device group up 10%). While we're raising our PO slightly to $24 (from $23), we find it difficult to justify a higher valuation without expecting meaningful upside to 2013 estimates, which we believe is unlikely. On the top-line, both guidance and consensus for 2013 call for pro forma revenue growth of 5-6%, which implies an acceleration from the 3% level seen in fiscal Q1 to 6-8% in the back half of the year."
Hologic closed at $22.75 on Tuesday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in